Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.
General Education Center, The University of Tokyo Hospital, Japan.
Intern Med. 2021;60(10):1583-1588. doi: 10.2169/internalmedicine.5611-20. Epub 2021 May 15.
Secondary immune thrombocytopenic purpura (ITP) with non-Hodgkin lymphoma (NHL) is a rare disease. Although some treatment regimens are available for primary ITP, the treatment strategy for secondary ITP remains unconfirmed. We herein report a 79-year-old man who was diagnosed with secondary ITP with mantle cell lymphoma. Although intravenous immunoglobulin (IVIG) has been considered an effective option for secondary ITP, similar to the treatment of primary ITP, our patient did not benefit from IVIG. A literature review including the current report revealed that IVIG was ineffective in all treated patients. Secondary ITP with NHL should be treated differently from primary ITP.
继发于非霍奇金淋巴瘤的免疫性血小板减少性紫癜（ITP）较为罕见。虽然有一些治疗方案可用于原发性 ITP，但继发性 ITP 的治疗策略仍未得到证实。本文报告了一例 79 岁男性，诊断为伴有边缘区淋巴瘤的继发性 ITP。尽管静脉注射免疫球蛋白（IVIG）已被认为是继发性 ITP 的有效选择，与原发性 ITP 的治疗相似，但我们的患者并未从 IVIG 中获益。包括本报告在内的文献回顾显示，IVIG 对所有治疗患者均无效。继发于 NHL 的 ITP 应与原发性 ITP 区别对待。
